At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Closed 10-31 16:00:00 EDT
0.8780
+0.0510
+6.17%
盘后0.9000
+0.0220+2.51%
19:59 EDT
High1.11Low0.7300Vol7.56M
Open0.7898D1 Closing0.8270Amplitude45.95%
Mkt Cap2.57MTradable Cap2.33MTotal Shares2.93M
T/O7.10MT/O Rate284.80%Tradable Shares2.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Penguin Solutions Releases 2023 Environmental, Social, and Governance Report
Business Wire  ·  05:55
Penguin Solutions Releases 2023 Environmental, Social, and Governance Report
CLCT reports 9MFY2024 NPI of RMB930.2 mil, 5.1% lower y-o-y
Felicia Tan  ·  10-30 02:18
CLCT reports 9MFY2024 NPI of RMB930.2 mil, 5.1% lower y-o-y
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
GlobeNewswire  ·  10-24
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
GRI Bio Agrees to Exercise of Warrants at Reduced Price; Shares Fall Premarket After Doubling on Monday
MT Newswires Live  ·  10-22
GRI Bio Agrees to Exercise of Warrants at Reduced Price; Shares Fall Premarket After Doubling on Monday
GRI Bio Announces Exercise of Warrants
GlobeNewswire  ·  10-22
GRI Bio Announces Exercise of Warrants
Top Premarket Gainers
MT Newswires Live  ·  10-21
Top Premarket Gainers
GRI Bio presents preclinical data on GRI-0621 in IPF at ICLAF 2024
TIPRANKS  ·  10-16
GRI Bio presents preclinical data on GRI-0621 in IPF at ICLAF 2024
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
GlobeNewswire  ·  10-16
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Worthington Steel Releases 2024 Corporate Citizenship and Sustainability Report
Business Wire  ·  10-15
Worthington Steel Releases 2024 Corporate Citizenship and Sustainability Report
CareTrust Publishes Fourth Annual Corporate Sustainability Report
Business Wire  ·  10-10
CareTrust Publishes Fourth Annual Corporate Sustainability Report
GRI Bio Initiated at Buy by Ascendiant Capital
Dow Jones  ·  10-08
GRI Bio Initiated at Buy by Ascendiant Capital
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
GlobeNewswire  ·  10-07
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
Grainger Says FY Like-For-Like PRS Rental Growth At 6.3%
Reuters  ·  10-07
Grainger Says FY Like-For-Like PRS Rental Growth At 6.3%
DTE Energy Releases Annual CleanVision Sustainability Report; highlights progress providing customers cleaner, more reliability and affordable energy
GlobeNewswire  ·  10-04
DTE Energy Releases Annual CleanVision Sustainability Report; highlights progress providing customers cleaner, more reliability and affordable energy
CompoSecure Earns Sustainability Silver Medal from EcoVadis for Second Consecutive Year, Placing in the Top 15% of Companies Globally
GlobeNewswire  ·  10-03
CompoSecure Earns Sustainability Silver Medal from EcoVadis for Second Consecutive Year, Placing in the Top 15% of Companies Globally
Ryder Releases Corporate Sustainability Report and CDP Climate Change Response
Business Wire  ·  10-01
Ryder Releases Corporate Sustainability Report and CDP Climate Change Response
GRI Bio Gets Japan Patent for Natural Killer T Cell Modulators to Prevent, Treat Inflammatory Diseases
MT Newswires Live  ·  09-30
GRI Bio Gets Japan Patent for Natural Killer T Cell Modulators to Prevent, Treat Inflammatory Diseases
Chord Energy Releases 2023 Sustainability Report
PR Newswire  ·  09-30
Chord Energy Releases 2023 Sustainability Report
BRIEF-Gri Bio Granted Japan Patent For NKT Cell Modulators
Reuters  ·  09-30
BRIEF-Gri Bio Granted Japan Patent For NKT Cell Modulators
GRI Bio Inc - Interim Data Expected in Q4 2024, Topline Data in Q1 2025
THOMSON REUTERS  ·  09-30
GRI Bio Inc - Interim Data Expected in Q4 2024, Topline Data in Q1 2025

Introduction

Company Name.
GRI BIO INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.
Issue price:
--